25 June 2020 - NICE has today issued draft guidance for public consultation which does not recommend siponimod (Mayzent, Novartis) for treating secondary progressive multiple sclerosis.

Siponimod is licensed to treat this type of multiple sclerosis in adults with evidence of active disease, which means they have relapses or features of inflammatory activity that show up on an MRI scan.

Interferon beta-1b is currently the only disease-modifying treatment available for people with active secondary progressive multiple sclerosis. However, few people take it because it can cause side effects such as flu-like symptoms.

Read NICE press release